Multicenter randomized Phase III Trial of concurrent chemoradiotherapy(CCRT) with Cisplatin versus CCRT with Cisplatin and Paclitaxel for locally uterine cervix adenocarcinoma

2016 Fiscal Year Final Research Report

• Project/Area Number: 25462598
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: University of the Ryukyus
• Principal Investigator: Nagai Yutaka 琉球大学, 医学(系)研究科(研究院), 准教授 (70305209)
• Project Period (FY): 2013-04-01 – 2017-03-31
• Keywords: 子宮頸部腺癌 / 同時化学放射線療法 / 多施設共同研究 / 第Ⅲ相試験 / シスプラチン / パクリタキセル / 観察研究

Outline of Final Research Achievements

Concurrent chemoradiotherapy (CCRT) using cisplatin is gold-standard treatment for advanced carcinoma of the uterine cervix. Although it is unclear whether cisplatin-based concurrent chemoradiotherapy has the same effect on adenocarcinoma as on squamous cell carcinoma.To evaluate safety and efficacy of CCRT with cisplatin (CCRT-P) vs CCRT with cisplatin and paclitaxel (CCRT-TP) for locally uterine cervix adenocarcinoma, we conducted a pahse III study for CCRT-P vs CCRT-TP. Because of poor enrollment for this study, we had to decide early termination of this trial. Immediately after this, We planned a national survey by patient who received CCRT for locally uterine cervix adenocarcinoma at this time. The altenative study showed that CCRT-TP achieved much better overall survival for adenocarcinoma of the uterine cervix.

Free Research Field

婦人科腫瘍学